# US 2020/0390072 A1 · Identifying and characterizing genomic safe harbors (gsh) in humans and murine genomes, and viral and non-viral vector compositions for targeted integration at an identified gsh loci

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0390072 A1
- Document ID: US20200390072A1
- Status: Published application
- Kind: A1
- Application number: 16/977,517
- Filed: 2019-03-01
- Published: 2020-12-17
- Earliest claimed: 2018-03-02
- Assignees: Generation Bio Co.; University of Massachusetts
- Applicants: Generation Bio Co.; University of Massachusetts
- Inventors: Robert M. Kotin; Evin Hildebrandt
- Web page: https://patentgrep.com/patent/US20200390072A1

## CPC

- A01K 67/0278: Knock-in vertebrates, e.g. humanised vertebrates
- C12N 15/907: {in mammalian cells}
- C07K 16/2896: {against molecules with a "CD"-designation, not provided for elsewhere}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/861: Adenoviral vectors
- C12Q 1/701: {Specific hybridization probes}
- G16B 20/00: ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B 20/50: Mutagenesis
- G16B 25/20: Polymerase chain reaction [PCR]; Primer or probe design; Probe optimisation
- A01K 2217/072: maintaining or altering function, i.e. knock in
- A01K 2227/105: Murine
- A01K 2267/03: Animal model, e.g. for test or diseases
- C12N 2506/02: from embryonic cells
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- G16B 10/00: ICT specially adapted for evolutionary bioinformatics, e.g. phylogenetic tree construction or analysis
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY

## Abstract

The technology described herein relates to methods, compositions and in silico screening approaches for identifying and validating genomic safe harbors (GSHs) in mammalian genomes, including human genomes. Another aspects relates to recombinant nucleic acid vectors, including non-viral and viral vectors comprising a portion of the GSH loci, or gRNA sequences specific to a GSH loci, and methods for use of the vectors for insertion of a gene of interest into a GSH loci.

## Claims

### Claim 1

A method to identify genomic safe harbor (GSH) regions in a mammalian genome, comprising;
a. identifying the loci of the endogenous virus element (EVE) of the genome of ur-species or in related species within taxonomic rank order;
b. identifying the interspecific conserved loci in the human or mouse genome;
c. validating the loci as a genomic safe harbors in human or mouse germlines using at least one in vitro or in vivo assays selected from any one or more of:
i. insertion of a marker gene into the loci in human cells and measure marker gene expression in vitro;
ii. insertion of marker gene into orthologous loci in progenitor cells or stem cells and engraft the cells into immune-depleted mice and/or assess marker gene expression in all developmental lineages;
iii. differentiate hematopoietic CD34+ cells into terminally differentiated cell types, wherein the hematopoietic CD34+ cells have a marker gene inserted into the loci identified in step b; or
iv. generate transgenic knock-in mouse wherein the genomic DNA of the mouse has a marker gene inserted in the loci identified in step b, wherein the marker gene is operatively linked to a tissue specific or inducible promoter.

### Claim 2 (depends on 1)

The method of claim 1, wherein the GSH is intragenic or intergenic.

### Claim 3 (depends on 1)

The method of claim 1, wherein the EVE is a nucleic acid sequence encoding intronic or exonic viral nucleic acid, viral DNA or DNA copies of viral RNA.

### Claim 4 (depends on 3)

The method of claim 3, wherein the viral nucleic acid is non-retroviral nucleic acid or non-retroviral provirus.

### Claim 5 (depends on 4)

The method of claim 4, wherein the non-retroviral nucleic acid is from a parvovirus or circovirus.

### Claim 6 (depends on 5)

The method of claim 5, wherein the parvovirus is selected from group consisting of B19, minute virus of mice (mvm), RA-1, AAV, bufavirus, hokovirus, bocovirus, or any of the parvoviruses listing in Table 2 or Table 4A or Table 4B.

### Claim 7 (depends on 6)

The method of claim 6, wherein the parvovirus is AAV.

### Claim 8 (depends on 5)

The method of claim 5, wherein the circovirus is porcrine circovirus (PCV) (e.g., PCV-1, PCV-2).

### Claim 9 (depends on 4)

The method of claim 4, wherein the non-retroviral nucleic acid encodes non-structural and/or structural viral proteins, e.g., rep (replication) and/or cap (capsid) proteins.

### Claim 10 (depends on 1)

The method of claim 1, wherein the ur-species are selected from any of the group of: Cetacea, Chiropetera, Lagomorpha, Macropodiadae.

### Claim 11

A method to identify genomic safe harbor (GSH) regions in a mammalian genome, comprising;
a) performing comparative genomic approaches to:
i) compare the interspecific introns of collinearly organized and/or synteny organized genes between species to identify an enlarged intron in one species relative to another species, and/or
ii) compare intergenic distance (or space) between adjacent genes or selected genes that are collinearly organized or synteny organized between species to identify a large variation in the intergenic distance (or space);
b) selecting the enlarged intron in step a(i) or intergenic space between selected genes in step a(ii) as a loci for a genomic safe harbor;
c) validating the loci as a genomic safe harbor in human or mouse germlines using at least one in vitro or in vivo assays selected from any one or more of:
i. insertion of a marker gene into the loci in human cells and measure marker gene expression in vitro;
ii. insertion of marker gene into orthologous loci in progenitor cells or stem cells and engraft the cells into immune-depleted mice and/or assess marker gene expression in all developmental lineages;
iii. differentiate hematopoietic CD34+ cells into terminally differentiated cell types, wherein the hematopoietic CD34+ cells have a marker gene inserted into the loci identified in step b; or
iv. generate transgenic knock-in mouse wherein the genomic DNA of the mouse has a marker gene inserted in the loci identified in step b, wherein the marker gene is operatively linked to a tissue specific or inducible promoter.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

A nucleic acid vector comprising at least a portion of the genomic safe harbor (GSH) nucleic acid identified as a genomic safe harbor in the method of any of claims 1 to 11.

### Claim 13 (depends on 12)

The nucleic acid vector of claim 12, wherein the vector is a viral vector or a non-viral vector.

### Claim 14 (depends on 12)

The nucleic acid of claim 12, wherein the at least a portion of the GSH nucleic acid comprises the PAX5 genomic DNA or a fragment thereof.

### Claim 15 (depends on 12)

The nucleic acid vector of claim 12, wherein the GSH nucleic acid comprises an untranslated sequence or an intron of the PAX5 gene.

### Claim 16 (depends on 12)

The nucleic acid of claim 12, wherein the at least a portion of the GSH nucleic acid comprises the Kif5 genomic DNA or a fragment thereof.

### Claim 17 (depends on 12)

The nucleic acid vector of claim 12, wherein the GSH nucleic acid comprises an untranslated sequence or an intron of the Kif5 gene.

### Claim 18 (depends on 12)

The nucleic acid vector of claim 12, wherein the GSH nucleic acid is a nucleic acid selected from any of the nucleic acid sequences listed in Table 1A or Table 1B.

### Claim 19 (depends on 12)

The nucleic acid vector of claim 12, wherein the at least portion of the GSH comprises at least one modification as compared to the wild-type GSH sequence.

### Claim 20 (depends on 19)

The nucleic acid vector of claim 19, wherein the modification is a nucleic acid sequence comprising a restriction cloning site.

### Claim 21 (depends on 19)

The nucleic acid vector of claim 19, wherein the modification is a nucleic acid sequence comprising one or more target sites for one or more nucleases.

### Claim 22 (depends on 21)

The nucleic acid vector of claim 21, wherein the nuclease is selected from a zinc finger nuclease (ZFN), a TAL-effector domain nuclease (TALEN), or a CRISPR/Cas system.

### Claim 23 (depends on 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The nucleic acid vector of any of claims 12-21, wherein the portion of GSH nucleic acid is at least 1 kb in length.

### Claim 24 (depends on 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The nucleic acid vector of any of claims 12-22, wherein the portion of GSH nucleic acid is between 300-3 kb in length.

### Claim 25 (depends on 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The nucleic acid vector of any of claims 12-22, wherein the portion of the GSH is a target site for a guide RNA (gRNA).

### Claim 26 (depends on 25)

The nucleic acid vector of claim 25, wherein the gRNA is for a sequence-specific nuclease selected from any of: a TAL-nuclease, a zinc-finger nuclease (ZFN), a meganuclease, a megaTAL, or an RNA guide endonuclease (e.g., CAS9, cpf1, nCAS9).

### Claim 27 (depends on 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

The nucleic acid vector of any of claims 12-26, the nucleic acid vector is a non-viral vector selected from the group comprising: a plasmid, a minicircle, comsid, an artificial chromosome (e.g., BAC), a linear covalently closed (LCC) DNA vector (e.g., minicircles, minivectors and miniknots), a linear covalently closed (LCC) vector (e.g., MIDGE, MiLV, ministering, miniplasmids), a mini-intronic plasmid, a pDNA expression vector, or variants thereof.

### Claim 28 (depends on 12)

The nucleic acid vector of claim 12, wherein the viral vector is selected from any of the group comprising: rAd, rAAV, rHSV, poxvirus vectors, lentivirus, vaccinia virus vectors, HSV Type 1 (HSV-1)-AAV hybrid vectors, baclulovirus expression vector systems (BEVS), and variants thereof.

### Claim 29 (depends on 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

The nucleic acid vector of any of claims 12-27, wherein the vector composition is a minicircle.

### Claim 30 (depends on 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The nucleic acid vector of any of claims 12-28, wherein the vector composition is an AAV vector comprising a capsid protein.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

A nucleic acid vector composition comprising, in the following order:
a. a GSH 5′ homology arm,
b. a nucleic acid sequence comprising a restriction cloning site,
c. a GSH 3′ homology arm, and
wherein the 5′ homology arm and the 3′ homology arm bind to a target site located in a genomic safe harbor (GSH) locus identified in the method of any of claims 1 to 11, and wherein the 5′ and 3′ homology arms guide homologous recombination into a loci located within the genomic safe harbor.

### Claim 32 (depends on 31)

The vector composition of claim 31, wherein the 5′ and 3′ homology arms are between 30-2000 bp in length.

### Claim 33 (depends on 31, 32)

The vector composition of claim 31 or 32, further comprising, inserted at the restriction cloning site, at least one or more of the following:
a gene editing nucleic acid sequence;
a target site for one or more nucleases;
a nucleic acid of interest; or
a guide RNA (gRNA) for a RNA-guided DNA endonuclease.

### Claim 34 (depends on 33)

The vector composition of claim 33, wherein the gene editing nucleic acid sequence encodes a gene editing nucleic acid molecule selected from the group consisting of: a sequence-specific nuclease, one or more guide RNA (gRNA), CRISPR/Cas, a ribonucleoprotein (RNP) or any combination thereof.

### Claim 35 (depends on 34)

The vector composition of claim 34, wherein the sequence-specific nuclease comprises: a TAL-nuclease, a zinc-finger nuclease (ZFN), a meganuclease, a megaTAL, or an RNA guide endonuclease (e.g., CAS9, cpf1, nCAS9).

### Claim 36 (depends on 33)

The vector composition of claim 33, wherein the nucleic acid of interest is a miRNA, RNAi, encodes a therapeutic protein, antibody, peptide, suicide gene, apoptosis gene or any gene or combination of genes listed in Table 3.

### Claim 37 (depends on 31)

The vector composition of claim 31, further comprising a control element, promoter or regulatory element operatively linked to the nucleic acid of interest.

### Claim 38 (depends on 31, 32, 33, 34, 35, 36, 37)

The vector composition of any of claims 31-37, wherein nucleic acid of interest or gene editing nucleic acid sequence is in an orientation for integration in the GSH in a forward orientation.

### Claim 39 (depends on 31, 32, 33, 34, 35, 36, 37, 38)

The vector composition of any of claims 31-38, wherein nucleic acid of interest or gene editing nucleic acid sequence is in an orientation for integration in the GSH in a reverse orientation.

### Claim 40 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 31, 32, 33, 34, 35, 36, 37, 38, 39)

The vector composition of any of claims 31-39, wherein GSH 5′ homology arm and the GSH 3′ homology arm bind to target sites that are spatially distinct nucleic acid sequences in the genomic safe harbor identified in the method of any of claims 1 to 11.

### Claim 41 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40)

The vector composition of any of claims 31-40, wherein the GSH 5′ homology arm and the GSH 3′ homology arm are at least 65% complementary to a target sequence in the genomic safe harbor locus identified in the method of any of claims 1 to 11.

### Claim 42 (depends on 31, 32, 33, 34, 35, 36, 37, 38, 39, 40)

The vector composition of any of claims 31-40, wherein the GSH 5′ homology arm and the 3′ homology arm bind to a target site located in the PAX5 genomic safe harbor sequence.

### Claim 43 (depends on 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The vector composition of any of claims 31-42, wherein the GSH 5′ homology arm and the GSH 3′ homology arm are at least 65% complementary to at least part the PAX5 genomic safe harbor sequence.

### Claim 44 (depends on 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41)

The vector composition of any of claims 31-41, wherein the GSH 5′ homology arm and the GSH 3′ homology arm bind to a GSH of target site located in a gene selected from Table 1A or 1B.

### Claim 45 (depends on 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

The vector composition of any of claims 31-44, wherein the nucleic acid vector is a non-viral vector selected from the group consisting of: a plasmid, a minicircle, comsid, an artificial chromosome (e.g., BAC), a linear covalently closed (LCC) DNA vector (e.g., minicircles, minivectors and miniknots), a linear covalently closed (LCC) vector (e.g., MIDGE, MiLV, ministering, miniplasmids), a mini-intronic plasmid, a pDNA expression vector, or variants thereof.

### Claim 46 (depends on 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

The vector composition of any of claims 31-44, wherein the nucleic acid is a viral vector selected from the group consisting of: rAd, rAAV, rHSV, poxvirus vectors, lentivirus, vaccinia virus vectors, HSV Type 1 (HSV-1)-AAV hybrid vectors, baclulovirus expression vector systems (BEVS) and variants thereof.

### Claim 47 (depends on 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

The vector composition of any of claims 31-44, wherein the vector composition is a minicircle.

### Claim 48 (depends on 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

The vector composition of any of claims 31-44, wherein the vector composition is a AAV vector comprising a capsid protein.

### Claim 49 (depends on 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48)

A cell comprising the vector composition of any of claims 12-48.

### Claim 50 (depends on 49)

The cell of claim 49, wherein the cell is a red blood cell (RBC) or RBC precursor cell.

### Claim 51 (depends on 50)

The cell of claim 50, wherein the RBC precursor cell is a CD44+ or CD34+ cell.

### Claim 52 (depends on 49)

The cell of claim 49, wherein the cell is a stem cell.

### Claim 53 (depends on 49)

The cell of claim 49, wherein the cell is an iPS cell or embryonic stem cell.

### Claim 54 (depends on 54)

The cell of claim 54, wherein the iPS cell is a patient-derived iPSC.

### Claim 55 (depends on 49, 50, 51, 52, 53, 54)

The cell of any of claims 49-54, wherein the cell is a mammalian cell.

### Claim 56 (depends on 55)

The cell of claim 55, wherein the mammalian cell is a human cell.

### Claim 57 (depends on 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48)

A method for inserting a nucleic acid of interest or gene editing nucleic acid sequence into a genomic safe harbor (GSH) loci of a cell, the method comprising introducing the vector of any of claims 31-48 into the cell, whereby homologous recombination of 3′ and 5′ homology arms with regions of the GSH integrate the nucleic acid sequence or gene editing nucleic acid sequence into the GSH loci.

### Claim 58 (depends on 57)

The method of claim 57, wherein the nucleic acid sequence is integrated into the GSH in a forward orientation.

### Claim 59 (depends on 57)

The method of claim 57, wherein the nucleic acid sequence is integrated into the GSH in a reverse orientation.

### Claim 60

A cell comprising an integrated nucleic acid of interest or gene editing nucleic acid sequence located in a genomic safe harbor (GSH) loci selected from Table 1A or 1B.

### Claim 61 (depends on 56, 60)

The cell of claim 60, produced by the method of claim 56.

### Claim 62 (depends on 60, 61)

The cell of claim 60 or 61, wherein the cell is a red blood cell (RBC) or RBC precursor cell.

### Claim 63 (depends on 62)

The cell of claim 62, wherein the RBC precursor cell is a CD44+ or CD34+ cell.

### Claim 64 (depends on 60, 61)

The cell of any of claims 60-61, wherein the cell is a stem cell.

### Claim 65 (depends on 60, 61)

The cell of any of claims 60-61, wherein the cell is an iPS cell or embryonic stem cell.

### Claim 66 (depends on 60, 61, 62, 63, 64, 65)

The cell of any of claims 60-65, wherein the iPS cell is a patient-derived iPSC.

### Claim 67 (depends on 60, 61, 62, 63, 64, 65, 66)

The cell of any of claims 60-66, wherein the cell is a mammalian cell.

### Claim 68 (depends on 67)

The cell of claim 67, wherein the cell is a human cell.

### Claim 69

A transgenic organism comprising an integrated nucleic acid of interest or gene editing nucleic acid sequence located in a genomic safe harbor loci selected from Table 1A or 1B.

### Claim 70 (depends on 56, 69)

The transgenic organism of claim 69, wherein the nucleic acid of interest or gene editing nucleic acid sequence is integrated into the GSH loci according to the method of claim 56.

### Claim 71 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48)

A kit comprising:
a. A vector composition of any of claims 31-48; and
b. at least one GSH 5′ primer and at least one GSH 3′ primer, wherein the GSH is identified by the method of any of claims 1 to 11, wherein the at least one GSH 5′ primer binds to a region of the GSH upstream of the site of integration, and the at least one GSH 3′ primer is at least binds to a region of the GSH downstream of the site of integration; and/or
i. at least two GSH 5′ primers comprising a forward GSH 5′ primer that binds to a region of the GSH upstream of the site of integration, and a reverse GSH 5′ primer that binds to a sequence in the nucleic acid inserted at the site of integration in the GSH sequence, wherein the GSH is identified by the method of any of claims 1 to 11.
c. at least two GSH 3′ primers comprising a forward GSH 3′ primer that binds to a sequence located at the 3′ end of the nucleic acid inserted at the site of integration in the GSH sequence, and a reverse GSH 3′ primer binds to a region of the GSH downstream of the site of integration, and wherein the GSH is identified by the method of any of claims 1 to 11.

### Claim 72 (depends on 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48)

A kit comprising:
(a) a GSH-specific single guide and an RNA guided nucleic acid sequence comprised in one or more GSH vectors; and
(b) GSH knock-in vector comprising GSH vector,
wherein one or more of the sequences of (a) or (b) are comprised on a vector of any of claims 31-48.

### Claim 73 (depends on 72)

The kit of claim 72, wherein the GSH vector is a GSH-CRISPR-Cas vector.

### Claim 74 (depends on 72)

The kit of claim 72, wherein the GSH CRISPR-Cas vector comprises a GSH-sgRNA nucleic acid sequence and Cas9 nucleic acid sequence.

### Claim 75 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 72)

The kit of claim 72, comprising a GSH knockin-donor vector comprising a GSH 5′ homology arm and a GSH 3′ homology arm, wherein the GSH 5′ homology arm and the GSH 3′ homology arm are at least 65% complementary to a sequence in the genomic safe harbor (GSH) identified in the method of any of claims 1 to 11, and wherein the GSH 5′ and 3′ homology arms guide insertion by homologous recombination, of the nucleic acid sequence located between the GSH 5′ homology arm and a GSH 3′ homology arm into a loci located within the genomic safe harbor identified in the method of claim 1 or 11.

### Claim 76 (depends on 72)

The kit of claim 72, wherein the GSH knockin-donor vector is a PAX5 knockin-donor vector comprising a PAX5 5′ homology arm and a PAX5 3′ homology arm, wherein the PAX5 5′ homology arm and the PAX5 3′ homology arm are at least 65% complementary to the PAX5 genomic safe harbor loci, and wherein the PAX5 5′ and 3′ homology arms guide insertion, by homologous recombination, of the nucleic acid located between the GSH 5′ homology arm and a GSH 3′ homology arm into a loci within the PAX5 genomic safe harbor.

### Claim 77 (depends on 72)

The kit of claim 72, wherein the GSH knockin-donor vector is a knockin donor vector comprising a 5′ homology arm which binds to a GSH loci listed in Table 1A or 1B, and a 3′ homology arm which binds to a spatially distinct region of the same GSH loci that the 5′ homology arm binds to, wherein the 5′ and 3′ homology arms guide insertion, by homologous recombination, of the nucleic acid located between the GSH 5′ homology arm and a GSH 3′ homology arm into a GSH loci listed in Table 1A or 1B.

### Claim 78 (depends on 72)

The kit of claim 72, wherein the GSH vector is GSH Cas9 knock in donor vector.

### Claim 79 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 72, 73, 74, 75, 76, 77, 78)

The kit of any of claims 72-78, further comprising at least one GSH 5′ primer and at least one GSH 3′ primer, wherein the GSH is identified by the method of any of claims 1 to 11, wherein the at least one GSH 5′ primer is at least 80% complementary to a region of the GSH upstream of the site of integration, and the at least one GSH 3′ primer is at least 80% complementary to a region of the GSH downstream of the site of integration.

### Claim 80 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 72, 73, 74, 75, 76, 77, 78, 79)

The kit of any of claims 72-79, further comprising at least two GSH 5′ primers comprising;
a. a forward GSH 5′ primer that is at least 80% complementary to a region of the GSH upstream of the site of integration, and
b. a reverse GSH 5′ primer that is at least 80% complementary to a sequence in the nucleic acid inserted at the site of integration in the GSH sequence,
wherein the GSH is identified by the method of any of claims 1 to 11.

### Claim 81 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 72, 73, 74, 75, 76, 77, 78, 79, 80)

The kit of any of claims 72-80, further comprising at least two GSH 3′ primers comprising;
a. a forward GSH 3′ primer that is at least 80% complementary to a sequence located at the 3′ end of the nucleic acid inserted at the site of integration in the GSH sequence, and
b. a reverse GSH 3′ primer that is at least 80% complementary to a region of the GSH downstream of the site of integration, and
wherein the GSH is identified by the method of any of claims 1 to 11.

### Claim 82 (depends on 72, 73, 74, 75, 76, 77, 78, 79, 80, 81)

The kit of any of claims 72-81, wherein the GSH 5′ primer is a PAX5 5′ primer and the GSH 3′ primer is a PAX 3′ primer, wherein the PAX5 5′ primer and the PAX5 3′ primer flank the site of integration in the PAX5 genomic safe harbor.

### Claim 83 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

A transgenic mouse comprising a marker gene inserted into the genomic DNA of the mouse at a GSH loci identified according to the methods of any of claims 1 to 11, wherein the reporter gene is flanked by lox sites.

### Claim 84 (depends on 83)

The transgenic mice of claim 83, wherein the lox sites are LoxP sites.

### Claim 85 (depends on 83)

The transgenic mice of claim 83, wherein the GSH loci is located in the genomic DNA of any of the genes selected from Table 1A or 1B.

### Claim 86 (depends on 83)

The transgenic mice of claim 83, wherein the GSH loci is located in the intronic or untranslated region (e.g., 3′UTR, 5′UTR exonic) nucleic acid sequence of the PAX5 gene or Kif1 gene.

### Claim 87 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

A method of generating a genetically modified animal comprising a nucleic acid interest inserted at a Genomic Safe Harbor (GSH) loci identified according to the method of any of claims 1 to 11, comprising a) introducing into a host cell a vector of any of claims 24-42, and b) introducing the cell generated in (a) into a carrier animal to produce a genetically modified animal.

### Claim 88 (depends on 87)

The method of claim 87, wherein the host cell is a zygote or a pluripotent stem cell.

### Claim 89 (depends on 87)

A genetically modified animal produced by the method of claim 87.

### Claim 90

A recombinant dependoparvovirus vector comprising a capsid, wherein the capsid comprises at least one GSH nucleic acid sequence.

### Claim 91 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 90)

The recombinant dependoparvovirus vector of claim 90, wherein the GSH nucleic acid sequence is identified by the method of any of claims 1-11.

### Claim 92 (depends on 90)

The recombinant dependoparvovirus vector of claim 90, wherein the GSH nucleic acid sequence is an EVE.

### Claim 93 (depends on 91, 92)

The recombinant dependoparvovirus vector of claim 91 or 92, wherein the capsid comprises sequence that is not found in the capsids of any of wild-type AAV I, II, III, IV, V, VI, VII, VIII or IX.

### Claim 94 (depends on 90, 91, 92, 93)

The recombinant dependoparvovirus vector of any of claims 90-93, wherein the dependoparvovirus is an AAV.
